Patents by Inventor Theodore E. Maione

Theodore E. Maione has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Therapeutic Uses of Mu-Opiate Receptor Peptides
    Publication number: 20230212221
    Abstract: The present invention pertains to novel uses of endomorphine-1 peptide, analogs, and salts thereof for therapy of children, patients currently suffering from drug addiction, patients prone to opioid addiction, and patients with chemo-induced pain.
    Type: Application
    Filed: December 27, 2022
    Publication date: July 6, 2023
    Inventor: Theodore E. MAIONE
  • Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
    Patent number: 11603385
    Abstract: The subject invention provides compositions and methods for alleviating pain. Specifically, the subject invention provides pharmaceutical formulations of peptides, and/or their salts, having advantageous ?-opioid receptor binding activity.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: March 14, 2023
    Assignee: CYTOGEL PHARMA, LLC
    Inventors: Theodore E. Maione, Constantine Basil Maglaris
  • ADVANTAGEOUS SALTS OF MU-OPIATE RECEPTOR PEPTIDES
    Publication number: 20220324908
    Abstract: The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their crystal structure, stability, solubility, lack of impurities and/or the ability to be produced, with these advantageous properties, in amounts sufficient for the production of therapeutic compositions.
    Type: Application
    Filed: December 17, 2021
    Publication date: October 13, 2022
    Inventor: Theodore E. MAIONE
  • Materials and Methods for Treatment of Inflammation
    Publication number: 20220249593
    Abstract: The subject invention pertains to peptides and salts thereof that are useful as anti-inflammatory agents and to compositions containing such peptides and salts as active ingredients. Specifically exemplified herein are endomorphin-1 peptide (EM-1), analogs and salts thereof, and uses for modulation of calcitonin gene-related peptide (CGRP) production and/or substance P (SP) and for treatment of inflammation, particularly neurogenic inflammation.
    Type: Application
    Filed: April 21, 2022
    Publication date: August 11, 2022
    Inventors: THEODORE E. MAIONE, CONSTANTINE BASIL MAGLARIS
  • POLYMER AGONISTS OF MU OPIOID RECEPTORS
    Publication number: 20220251139
    Abstract: The subject invention provides compositions and methods for alleviating pain. Specifically, the subject invention provides pharmaceutical formulations of polymers, and/or their salts, having advantageous ?-opioid receptor binding activity.
    Type: Application
    Filed: April 20, 2022
    Publication date: August 11, 2022
    Inventors: THEODORE E. MAIONE, JAMES HAMSHER, CONSTANTINE BASIL MAGLARIS
  • Materials and methods for treatment of inflammation
    Patent number: 11324798
    Abstract: The subject invention pertains to peptides and salts thereof that are useful as anti-inflammatory agents and to compositions containing such peptides and salts as active ingredients. Specifically exemplified herein are endomorphin-1 peptide (EM-1), analogs and salts thereof, and uses for modulation of calcitonin gene-related peptide (CGRP) production and/or substance P (SP) and for treatment of inflammation, particularly neurogenic inflammation.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: May 10, 2022
    Assignee: CYTOGEL PHARMA, LLC
    Inventors: Theodore E. Maione, Constantine Basil Maglaris
  • ADVANTAGEOUS MU-OPIATE RECEPTOR PEPTIDE COMPOUNDS
    Publication number: 20210277057
    Abstract: The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their activity.
    Type: Application
    Filed: May 24, 2021
    Publication date: September 9, 2021
    Inventor: Theodore E. MAIONE
  • Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
    Patent number: 10975121
    Abstract: The subject invention provides compositions and methods for alleviating pain. Specifically, the subject invention provides pharmaceutical formulations of peptides, and/or their salts, having advantageous ?-opioid receptor binding activity.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: April 13, 2021
    Assignee: CYTOGEL PHARMA, LLC
    Inventors: Theodore E. Maione, Constantine Basil Maglaris
  • ANALGESIC MU-OPIOID RECEPTOR BINDING PEPTIDE PHARMACEUTICAL FORMULATIONS AND USES THEREOF
    Publication number: 20210017225
    Abstract: The subject invention provides compositions and methods for alleviating pain. Specifically, the subject invention provides pharmaceutical formulations of peptides, and/or their salts, having advantageous ?-opioid receptor binding activity.
    Type: Application
    Filed: October 2, 2020
    Publication date: January 21, 2021
    Inventors: Theodore E. MAIONE, Constantine Basil MAGLARIS
  • Materials and Methods for Treatment of Inflammation
    Publication number: 20200360463
    Abstract: The subject invention pertains to peptides and salts thereof that are useful as anti-inflammatory agents and to compositions containing such peptides and salts as active ingredients. Specifically exemplified herein are endomorphin-1 peptide (EM-1), analogs and salts thereof, and uses for modulation of calcitonin gene-related peptide (CGRP) production and/or substance P (SP) and for treatment of inflammation, particularly neurogenic inflammation.
    Type: Application
    Filed: August 6, 2020
    Publication date: November 19, 2020
    Inventors: THEODORE E. MAIONE, CONSTANTINE BASIL MAGLARIS
  • ADVANTAGEOUS SALTS OF MU-OPIATE RECEPTOR PEPTIDES
    Publication number: 20200339628
    Abstract: The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their crystal structure, stability, solubility, lack of impurities and/or the ability to be produced, with these advantageous properties, in amounts sufficient for the production of therapeutic compositions.
    Type: Application
    Filed: July 15, 2020
    Publication date: October 29, 2020
    Inventor: Theodore E. MAIONE
  • NOVEL THERAPEUTIC USES OF MU-OPIATE RECEPTOR PEPTIDES
    Publication number: 20200331962
    Abstract: The present invention pertains to novel uses of endomorphine-1 peptide, analogs, and salts thereof for therapy of children, patients currently suffering from drug addiction, patients prone to opioid addiction, and patients with chemo-induced pain.
    Type: Application
    Filed: July 6, 2020
    Publication date: October 22, 2020
    Inventor: Theodore E. MAIONE
  • POLYMER AGONISTS OF MU OPIOID RECEPTORS
    Publication number: 20200270304
    Abstract: The subject invention provides compositions and methods for alleviating pain. Specifically, the subject invention provides pharmaceutical formulations of polymers, and/or their salts, having advantageous ?-opioid receptor binding activity.
    Type: Application
    Filed: November 19, 2018
    Publication date: August 27, 2020
    Inventors: THEODORE E. MAIONE, JAMES HAMSHER, CONSTANTINE BASIL MAGLARIS
  • Materials and methods for treatment of inflammation
    Patent number: 10441625
    Abstract: The subject invention pertains to peptides and salts thereof that are useful as anti-inflammatory agents and to compositions containing such peptides and salts as active ingredients. Specifically exemplified herein are endomorphin-1 peptide (EM-1), analogs and salts thereof, and uses for modulation of calcitonin gene-related peptide (CGRP) production and/or substance P (SP) and for treatment of inflammation, particularly neurogenic inflammation.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: October 15, 2019
    Assignee: CYTOGEL PHARMA, LLC
    Inventors: Theodore E. Maione, Constantine Basil Maglaris
  • MATERIALS AND METHODS FOR TREATMENT OF INFLAMMATION
    Publication number: 20190307831
    Abstract: The subject invention pertains to peptides and salts thereof that are useful as anti-inflammatory agents and to compositions containing such peptides and salts as active ingredients. Specifically exemplified herein are endomorphin-1 peptide (EM-1), analogs and salts thereof, and uses for modulation of calcitonin gene-related peptide (CGRP) production and/or substance P (SP) and for treatment of inflammation, particularly neurogenic inflammation.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 10, 2019
    Inventors: THEODORE E. MAIONE, CONSTANTINE BASIL MAGLARIS
  • NOVEL ANALGESIC PHARMACEUTICAL FORMULATIONS AND USES THEREOF
    Publication number: 20180371017
    Abstract: The subject invention provides compositions and methods for alleviating pain. Specifically, the subject invention provides pharmaceutical formulations of peptides, and/or their salts, having advantageous ?-opioid receptor binding activity.
    Type: Application
    Filed: April 25, 2018
    Publication date: December 27, 2018
    Inventors: Theodore E. MAIONE, Constantine Basil MAGLARIS
  • Materials and Methods for Treatment of Inflammation
    Publication number: 20180311303
    Abstract: The subject invention pertains to peptides and salts thereof that are useful as anti-inflammatory agents and to compositions containing such peptides and salts as active ingredients. Specifically exemplified herein are endomorphin-1 peptide (EM-1), analogs and salts thereof, and uses for modulation of calcitonin gene-related peptide (CGRP) production and/or substance P (SP) and for treatment of inflammation, particularly neurogenic inflammation.
    Type: Application
    Filed: July 13, 2018
    Publication date: November 1, 2018
    Inventors: Theodore E. MAIONE, Joseph CAROZZA, C. Dean MAGLARIS
  • ADVANTAGEOUS SALTS OF MU-OPIATE RECEPTOR PEPTIDES
    Publication number: 20180291060
    Abstract: The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their crystal structure, stability, solubility, lack of impurities and/or the ability to be produced, with these advantageous properties, in amounts sufficient for the production of therapeutic compositions.
    Type: Application
    Filed: June 22, 2018
    Publication date: October 11, 2018
    Inventor: Theodore E. Maione
  • NOVEL THERAPEUTIC USES OF MU-OPIATE RECEPTOR PEPTIDES
    Publication number: 20180282370
    Abstract: The present invention pertains to novel uses of endomorphine-1 peptide, analogs, and salts thereof for therapy of children, patients currently suffering from drug addiction, patients prone to opioid addiction, and patients with chemo-induced pain.
    Type: Application
    Filed: June 13, 2018
    Publication date: October 4, 2018
    Inventor: Theodore E. MAIONE
  • ADVANTAGEOUS MU-OPIATE RECEPTOR PEPTIDE COMPOUNDS
    Publication number: 20180251490
    Abstract: The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their activity.
    Type: Application
    Filed: May 16, 2018
    Publication date: September 6, 2018
    Inventor: Theodore E. Maione